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Abstract
NR0B1 (nuclear receptor subfamily 0, group B, member 1) is a transcription factor encoded by DAX1 (dosage-sensitive sex 
reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) responsible for the development and maintenance of 
the steroidogenic tissues. In humans the DAX1 mutations cause congenital adrenal hypoplasia (AHC) and hypogonadotropic 
hypogonadism (HHG) in boys. Here we report two brothers who were assessed by endocrinologist at the age of 51 and 43 
because of their serious osteoporosis. They had been substituted with prednisolone since the age of 4 and 9 years because 
of their primary adrenal insufficiency (PAI). Due to their late puberty caused by HHG at the age of 16 and 17 years their 
heights were − 3.1 and − 3.3 SD, but then they had a significant growth during their adulthood and reached the + 1.85 SD 
and + 3.78 SD respectively. During this period, they received glucocorticoid supplementation, but the treatment of their 
HHG was inadequate. At the age of 51 and 43 years insulin tolerance test (ITT) and gonadotropin releasing hormone (GnRH) 
test confirmed their PAI and HHG. Genetic test performed at this time revealed a novel, four nucleotides deletion (del.586-
571c.GGGC or 572-575c.GGGC) of DAX1 gene. The two brothers with AHC and HHG caused by a novel DAX1 mutation, 
reached tall final heights, despite of the disadvantageous prednisolone treatment during their childhood. We assume that 
the long-term lack of the sexual hormone substitution was a significant reason of their above average height as well as their 
serious osteoporosis.
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Introduction
The DAX1 is located on the short arm of X chromosome 
and is also known as NR0B1 (OMIM*300473), encoding 
an orphan nuclear hormone receptor (NHR) [1].
DAX-1 is expressed in embryonic stem cells, steroido-
genic tissues (gonads, adrenals), ventromedial hypothala-
mus as well as pituitary gland in developing and adult 
tissues [2, 3]. The exact mechanism of DAX1 in different 
transcriptional processes remains unclear, but it has shown 
that it can function as a repressor during the transcription 
or can have a role as an RNA shuttling protein [1, 4–9].
In case of the loss of DAX1 function due to mutations 
develops an AHC and HHG in boys, although the pheno-
typic variation of severity and the age of manifestation 
are highly variable [10–12]. Even animal models indicate 
that DAX1 also plays a primary role in the development 
of testis and spermatogenesis [13].
In AHC patients the permanent zone of adrenal cortex 
is absent and abnormally large fetal adrenal cells persist, 
resulting in a structural and functional disorganization of 
the adrenal gland with consequent different severity of glu-
cocorticoids, mineralocorticoids and androgens deficien-
cies [14, 15]. In patients with AHC the current treatment 
indicates maintenance of glucocorticoid and mineralocor-
ticoid replacement and appropriate symptomatic treatment 
during adrenal crises [12, 16].
HHG is caused by combined and variable deficiency of 
hypothalamic failure in gonadotropin-releasing hormone 
(GnRH) producing and pituitary defect in responsiveness 
to GnRH, resulting in reduced gonadotropin production 
[17]. Treating HHG in affected boys requires gonadotro-
pins and/or sexual hormone substitution during puberty 
and lifelong [12].
Here we report two brothers who had been substituted 
with glucocorticoids since their childhood due to their 
AHC and partially with sexual hormone since their late 
teenage because of their HHG. The final diagnosis was 
achieved by genetic testing demonstrating a novel, four 
nucleotides deletion of DAX1.
Case Reports
Patient 1
The 51-age patient was referred to the endocrinologist 
because of a serious osteoporosis (T-score lumbar: − 2.3 
hip: − 2.5). At this point his height was188 cm and he had 
a hypogonad phenotype with gynecomastia and hypoplas-
tic testes (2 ml × 2 ml).
He was born at term from an uneventful pregnancy 
with 4400 gramm birthweight, from non-consanguineous 
healthy average height parents. However, during family 
history turned out that but one of his maternal uncles died 
in infancy.
After an unremarkable early childhood, the 4-year-old 
boy was hospitalized several times because of the repeat-
ing classical symptoms of hypadrenia (hyperpigmenta-
tion, failed to thrive, stomachache, vomiting). Based on 
the clinical findings and laboratory results the diagnosis 
of primary hypadrenia was established. The possibil-
ity of 21-hydroxylase deficiency was excluded, but he 
received antituberculotic treatment. Karyotype revealed 
46,XY male genotype. Per os prednisolone 2.5 mg/die and 
decosterone intramuscular injection (1 × 5 mg/week) were 
introduced.
Due to bilateral cryptorchidism he was treated with 
intramuscular HCG (human choriogonadotropin) but 
because of the inefficacy of this treatment he underwent 
an orchidopexy at age 11 years.
His puberty was delayed and since the age of 23 years 
he received regular HCG treatment (3000 IU/2 months) 
and then the level of testosterone achieved the 9 nmol/l, 
testis and pubic hair were growing. Because of compli-
ance problem from the age of 25 years until 51 years he 
remained untreated with testosterone replacement, but he 
has been receiving glucocorticoid supplementation (hydro-
cortisone 40 mg/day).
His growth curve was unusual (13 years 147 cm: − 1.26 
SD, 16 years 152 cm: − 3.1 SD, 23 years 166 cm: − 1.68 
SD) but at adult age (51 years) he reached 188 cm (1.85 
SD) and his weight was 95 kg (BMI: 26.9 kg/m2).
Exactly at this age the diagnoses of PAI and HHG were 
confirmed by gonadotropin releasing hormone (GnRH) 
and the Insulin tolerance tests (ITT) (Table 1). These 
tests revealed a low level of the gonadotropic hormones, 
peak luteinizing hormone (LH): 0.3 IU/l and peak Fol-
licle stimulating hormone (FSH): 1.6 IU/l, low cortisol 
(3.5 nmol/l), elevated ACTH (Adrenocorticotropic hor-
mone) (> 330 pg/ml) and low growth hormone (GH) level 
(peak: 0.25 mIU/l). The brain magnetic resonance (MR) 
imaging showed normal brain anatomy and a lack of pitui-
tary anomalies.
Molecular genetic examination revealed a novel, four 
nucleotides deletion of DAX1 gene confirming the diag-
nosis of congenital adrenal hypoplasia.
From that time his treatment regimen includes hydro-
cortisone 30  mg/day (13  mg/m2/day hydrocortisone), 
0.1 mg fludrocortisone/day, mesterolone 50 mg/day, alen-
dronic acide 70 mg/week and vitamin D 3000  IU/day. 
Upon androgen substitution (testosterone undecanoate 
1000 mg) he had a priapism and he refused this therapy.
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Patient 2
He is a younger brother of the Patient 1 and he was also 
evaluated by the endocrinologist at the age of 43 years 
because of a serious osteoporosis (T-score, lumbar − 2.6, 
hip: − 2.5). His height was 200 cm presenting with a hypo-
gonad phenotype: gynecomastia, 2 ml testes and a hypo-
plastic penis.
He was born from an uneventful pregnancy at term with 
4700 gr birth weight. At the age of 9 years, based on the 
clinical symptoms (easily exhausted, failure to thrive, stom-
achache, repeated vomiting) and the PAI of his brother, this 
diagnosis was also established for him. Karyotype revealed 
a 46,XY male genotype and 21-hydroxylase deficiency were 
excluded. Per os prednisolone 5 mg/die and decosterone 
intramuscular injection 1 × 5 mg/week were commenced.
As with his older brother, his puberty was also delayed 
and the patient was treated with HCG 3000 IU/2 months 
from the age of 17 years. Due to this treatment testis became 
larger and secondary signs of male gender developed. A few 
years later because of the adherence problem he stopped the 
HCG, although he still stayed on glucocorticoid treatment 
(hydrocortisone 20 mg/day).
His registered heights were: at 7 years 125 cm (0.47 SD), 
10 years: 131 cm (− 1.27 SD), 17 years: 155 cm (− 3.0 SD), 
43 years: 200 cm (+ 3.78 SD) and weight 120 kg (BMI: 
30 kg/m2).
At the age of 43 the diagnosis of PAI and HHG were 
proved by GnRH and ITT test. (Table  1). These tests 
revealed a low level of the gonadotropic hormones (peak LH: 
0.3 IU/L, peak FSH: 1.4 IU/l), low cortisol (27.3 nmol/l), 
elevated ACTH (111.2 pg/ml) and low GH level (peak: 
0.11 mIU/l). Similarly, to his brother the brain MR imaging 
revealed normal brain anatomy and a lack of any pituitary 
anomalies. In addition a molecular genetic examination 
showed the similar mutation detected in his brother.
From the age of 43 years his treatment included hydro-
cortisone 20 mg/day (8 mg/m2/day) hydrocortisone, mester-
olone 50 mg/day, 0.1 mg fludrocortisone/day and vitamin 
D 30,000 IU/week. Moreover the androgen substitution 
(testosterone undecanoate 1000 mg) caused the same pain-
ful priapism as his brother, he also refused the replacement 
therapy of male sexual hormone.
Molecular genetic analysis of DAX1 gene
Informed consent was obtained from the brothers and their 
mother for publication of their medical details. Molecu-
lar genetic examination of DAX1 was performed within 
the frame of the routine clinical genetic testing service 
at Clinical Genetics and Endocrinology Laboratory Sem-
melweis University following the institutional protocol. 
Genomic DNA was extracted from peripheral blood 
Table 1  Hormone 
concentrations in fasting and 
after endocrine stimulation (ITT 
and GnRH) tests in Patient 1 
and Patient 2
ACTH Adrenocorticotropic hormone, FSH Follicle stimulating hormone, fT4 free thyroxine, GnRH Gon-
adotropin releasing Hormone, GH Growth hormone, IGFI Insulin-like growth factor, LH Luteinizing hor-
mone, TSH Thyroid stimulating hormone
Patient 1 Patient 2 Reference range
Age 51 years 43 years
Basal hormone levels
 IGFI 169.5 96 92–244 UG/l
Male: 35 years: 80–240 ng/ml
Male: 45 years: 70–210 ng/ml
 Prolactin 171.8 371.8 54–380 mIU/l
 TSH 2.8 2.7 0.35–4.94 mIU/l
 fT4 17 10.5 9–19 pmol/l
 Testosterone < 0.28 0.33 5.8–28.1 nmol/l
 Renin activity 103.9 124.1 0.2–5.7 ng/ml/h
 Aldosterone 2.6 2.1 30–400 pg/ml
Insulin tolerance test
 Lowest glucose 2.2 2.0 < 2.2 mmol/l or half of the initial value
 Peak ACTH > 330 111.2 7.2–63.3 pg/ml
 Peak GH 0.25 0.11 0–6 ng/ml
 Peak cortisol 3.5 27.3 8–25 μg/dl
GnRH test
 Peak LH 0.3 0.3 1.7–8.6 IU/l
 Peak FSH 1.6 1.4 1.5–12 IU/l
 LH/FSH 0.19 0.21 > 1
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leukocytes using the DNA isolation kit for mammalian 
blood (Boehringer Mannheim Corporation, Indianapolis, 
IN, USA) and DNA samples were frozen at − 20 °C until 
they were analyzed. Mutation analysis of DAX1 gene 
was carried out using polymerase chain reaction (PCR) 
followed by direct bidirectional sequencing of the PCR-
amplified DNA. The oligonucleotide primer pairs used for 
PCR amplification of exons 1 and 2 of DAX1 gene were 
as following:
1 AF: 5′-CGT GCG CGC TAG GTA TAA AT-3′
1 AR: 5′-GTT TGC TTT GCG CTC GTC-3′
1 BF: 5′-CAG GGC AGC ATC CTC TAC A-3′
1 BR: 5′-AAG CAG CAG CGG TAC AGA AG-3′
1 CF: 5′-CTT CTG TAC CGC TGC TGC TT-3′
1 CR: 5′-CCA CAG TCT CGA ACT GCA AG-3′
1 DF: 5′-CTT GCA GTT CGA GAC TGT GG-3′
1 DR: 5′-TTT TGT GAG CTG GGA AAA GC-3′
2 F: 5′-TTT TTC TCC CTC CAG ACG TG-3′
2 R: 5′-TCT TTT GCC CAC AGC TCT TT-3′
The PCR-amplified DNA was purified using a commer-
cial kit (High pure PCR product, Roche Diagnostics, Man-
nheim, Germany). For direct sequencing of the whole cod-
ing region of DAX1 gene, Sanger sequencing was used All 
sequences were compared to the NCBI reference sequence 
NG_009814.1.
Results
The clinical and endocrinological characteristics of the 
patients are summarized in Table 1. Direct sequencing 
of the NR0B1 (DAX1) gene revealed in both brothers a 
novel, four nucleotides deletion in the first exon (Fig. 1). 
The GGGC deletion is located in a sequence repetition 
GGG CGG GC, so deletion can be del.568-571c.GGGC or 
del.572-575.c.GGGC. This four nucleotides containing dele-
tion results in a frameshift and consequently the protein is 
terminated at an “ambush” Stop codon 788-790c. (Fig. 1). 
This mutation was also found in a heterozygous state in the 
patients’ healthy mother.
This variant has not been reported in any public databases 
such as dbSNP (http//:http://www.ncbi.nlm.nih.gov/proje ct/
SNP), ClinVar (https ://www.ncbi.nlm.nih.gov/clinv ar/) or 
ExAC (http//exac.broadinstitute.org).
Discussion
DAX is a member of the nuclear hormone receptor fam-
ily, although the homology is significant only in the puta-
tive carboxyl-terminal ligand binding domain (LBD). The 
DNA binding N terminal domain is substituted by an unu-
sual novel domain that contains three and half repeats of a 
Fig. 1  A novel four nucleotides 
deletion del.586-571c.GGGC or 
572-575c.GGGC of DAX1 gene 
in homozygous form
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65–67 amino-acid motif containing two putative zinc fingers 
[18, 19].
In the current cases the deletion (c.568-571/572-575) 
locates just before the start of the ligand-binding domain 
(codon 196) (Fig. 1). Even the protein translation continues 
the four nucleotide deletion results in a frameshift and the 
structure of this part of the protein is not intact anymore. 
The “ambush” Stop codon at nucleotides 788–790 nucleo-
tides cause deleterious damage of the ligand binding domain 
and this variant is considered pathogenic based on ACMG 
(American College of Medical Genetics) guideline.
DAX1 has a role in the maintenance of certain adult tis-
sues, according to the Human Protein Atlas (http://www.
prote inatl as.org/ENSG0 00001 69297 -NR0B1 /tissu e). It is 
expressed only in the adrenal gland, testis and ovaries, mak-
ing impossible to test the functional consequences of the 4 
nucleotides deletion on RNA level.
Several cases have been published when the LBD was 
abolished and the symptoms of hypadrenia were presented 
only in childhood [18]. Nevertheless, even carrying the same 
mutation the age of the appearance of clinical symptoms 
can be very various [20]. One of the possible explanations 
of these facts is the differences in salvage mechanisms for 
persistence of fetal adrenal, which suggests that other fac-
tors, including epigenetics and protein modifications may be 
involved in the process [21, 22].
Affected boys with HHG fail to undergo puberty and 
require sexual hormone substitution. Repeated injections of 
hCG (human Choriogonadotropin) are generally successful 
in stimulating the testosterone production of the testis, but 
in practice the more accepted method is to use external tes-
tosterone replacement treatment to induce puberty, and the 
maintenance of sex-hormone replacement during adulthood 
[16]. In our patients the hCG treatment was successful, but 
after a two-year period the patients refused the intramuscular 
treatment and they stayed on the glucocorticoid, but without 
male sexual hormone replacements for two decades. Then 
in their adulthood induced testosterone undecanoate caused 
a priapism and due to this painful experience, they have 
also refused the androgen substitution therapy. According to 
patients they had never had an active sexual life. We suppose 
the long insufficient androgen replacement led to late fusion 
of the epiphysis consequently the patients reached their final 
height only at the end of their twenties and a serious osteo-
porosis developed in their forties.
According to Kletter and his colleagues in congenital 
adrenal hypoplasia with gonadotropin deficiency, the defi-
cit in pituitary hormones is selective for gonadotropins (LH, 
FSH) and the other pituitary hormones’ production remains 
intact (ACTH, GH, TSH and PRL) [14]. In our patients the 
diagnosis was proved at the ages of 51 and 43 years, as an 
ITT and GnRH test were implemented and beside the AHC 
and HHG, a low level of GH was established coincidentally.
The recommendation of Bornstein and colleagues does 
not suggest the measurement of growth hormone level in 
the case of AHC including the DAX1 mutation suspect 
patients [23]. During the childhood of the brothers in Hun-
gary the only accessible glucocorticoid product was the 
5 mg prednisolone tablet. It is well known that the accurate 
dosing of this drug is difficult. Despite of this challenge, 
since introducing the prednisolone treatment the brothers 
had not had adrenal crisis and they did not show symp-
toms of overdose. From their young adult ages, they were 
treated with hydrocortisone. The Patient 1 required higher 
doses to be asymptomatic, but the Patient 2 was treated in 
substitution dose of hydrocortisone supplemented both of 
them with mineralocorticoid. Despite of the disadvanta-
geous prednisolone treatment on the bone maturation the 
final adult heights of the brothers were + 1.85 and + 3.78 
SD.
Calliari and colleagues published a case about a boy 
with DAX1 mutation and below average adult height. In 
this case the growth hormone level was not measured and 
the induction of puberty was started at 12 years of age due 
to psychological aspects [24]. In two patients published by 
Rojek the growth hormone deficiency was diagnosed at the 
age of 13 and 18 years respectively. In the second case, 
due to the retarded bone age, the latterly induced sexual 
hormone replacement and growth hormone therapy in the 
patient still showed growth at 23 years of age [25].
In cases of glucocorticoid treatment, the GH deficiency 
should be interpreted as a consequence of the excess of 
glucocorticoids substitution [25]. Although in our cases 
the suppressed ACTH level has not been proved, we could 
not exclude the harmful effect of glucocorticoids. However 
the fact, that the patients had still significant growth after 
16 years of age (35 and 45 cm) does not confirm the over-
dose of glucocorticoid administered during this period.
In our patients, beside the low normal range meas-
ured IGF level, significantly low GH concentration were 
detected during the ITT, which can be explained by the 
fact that they were not on adequate male sexual hormone 
therapy before and during the test. Nevertheless, we sup-
pose the main reason of the elevated BMI is their sedimen-
tary lifestyle which may be related to the mesterolone ther-
apy instead of a proper male sexual hormone replacement.
In conclusion, in our two male patients with AHC and 
HHG, caused by a novel DAX1 mutation despite of the long 
prednisolone treatment in their childhood they had reached a 
tall adult height. While the brothers had a significant growth 
during their adulthood, we assume the lack of the sexual 
hormone substitution was the main reason of their above 
average height as well as their serious osteoporosis.
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